Drug Patent List
First Filer Exclusivity TimelineNew
Newsletter
Weekly Digest

Pharsight

Life Drug Patent Portfolio

Life's Family Patents


Family Patents





Clinical Trials

Recent Clinical Trials by Life:

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema Eclipse Life Sciences, Inc. NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2
Safety and Efficacy of wSp Vaccine in Young Children Serum Life Science Europe GmbH NA RECRUITING
(Sep 1, 2026)
PHASE2
A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension YS Life Science Co., Ltd. NA RECRUITING
(Sep 1, 2026)
PHASE3
Unique Treatment of Oncology Pain in Advanced Cancer ZYUS Life Sciences Inc. NA COMPLETED
(Aug 1, 2026)
PHASE2
A Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer Beijing Gene Key Life Technology Co., Ltd NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2
Evaluating Safety and Efficacy of VV119 in Acute Schizophrenia Adults Vigonvita Life Sciences NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE2
Cenobamate Open-Label Extension Study for YKP3089C025 SK Life Science, Inc. NA COMPLETED
(Jun 1, 2026)
PHASE3
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer Shenzhen Ionova Life Sciences Co., Ltd. NA RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2
Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD Vigonvita Life Sciences NA RECRUITING
(May 1, 2026)
PHASE2
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer Achieve Life Sciences NA COMPLETED
(Apr 1, 2026)
PHASE3
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia ReAlta Life Sciences, Inc. NA RECRUITING
(Apr 1, 2026)
PHASE2
TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis Talengen Institute of Life Sciences, Shenzhen, P.R. China. NA RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML Sellas Life Sciences Group NA RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2
Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions) Life Biosciences Inc. NA RECRUITING
(Mar 1, 2026)
PHASE1


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List